Immunotherapy boosts chemotherapy in combating stage 3 colon cancer - Middle East Business News and Information
Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific genetic makeup called deficient DNA mismatch repair (dMMR) — was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone. Approximately 15% of people diagnosed with colon cancer exhibit dMMR and, to date, these tumors appear less sensitive to chemotherapy. The results of the multi-center study were presented during a plenary session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
'The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer,' says oncologist Frank Sinicrope, M.D., who led the study. 'It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival.'
Until now, the standard treatment after surgery for any stage 3 colon cancer has been chemotherapy. However, the researchers note that approximately 30% of patients experience cancer recurrence despite this treatment.
The clinical trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. The immunotherapy given in this study was an immune checkpoint inhibitor, known as atezolizumab, which activates one's immune system to attack and kill cancer cells, which are responsible for cancer recurrence and spread. The patients — who lived in the U.S. and Germany — received chemotherapy for six months along with immunotherapy and then continued with immunotherapy alone for another six months.
Dr. Sinicrope and others previously studied patients with colon cancer whose cells are unable to repair errors during DNA replication that create a nucleotide mismatch, a condition called dMMR. They noted that these patients' tumors showed a striking increase in inflammatory cells within the tumor, including those that express the target of immune checkpoint inhibitors. This sparked the idea of using immune checkpoint inhibitors to make the immune cells more effective in attacking and killing the cancer cells.
Based on the data from this study, Dr. Sinicrope recommends this combination of immunotherapy and chemotherapy treatment to be the new standard treatment for stage 3 deficient mismatch repair colon cancer. The research team plans to approach the National Comprehensive Cancer Network, a nonprofit organization consisting of 33 leading cancer centers, including Mayo Clinic, with this recommendation.
The study included patients with Lynch syndrome, the most common form of hereditary colon cancer, as these patients can have tumors that show deficient mismatch repair (dMMR).
'We're changing the paradigm in colon cancer treatment. By using immunotherapy at earlier stages of disease, we are achieving meaningful benefits for our patients,' says Dr. Sinicrope.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
7 days ago
- Mid East Info
Immunotherapy boosts chemotherapy in combating stage 3 colon cancer - Middle East Business News and Information
Dubai, United Arab Emirates;August 2025 — Colon cancer is the third most common cancer in the world. While screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged. Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific genetic makeup called deficient DNA mismatch repair (dMMR) — was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone. Approximately 15% of people diagnosed with colon cancer exhibit dMMR and, to date, these tumors appear less sensitive to chemotherapy. The results of the multi-center study were presented during a plenary session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 'The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer,' says oncologist Frank Sinicrope, M.D., who led the study. 'It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival.' Until now, the standard treatment after surgery for any stage 3 colon cancer has been chemotherapy. However, the researchers note that approximately 30% of patients experience cancer recurrence despite this treatment. The clinical trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. The immunotherapy given in this study was an immune checkpoint inhibitor, known as atezolizumab, which activates one's immune system to attack and kill cancer cells, which are responsible for cancer recurrence and spread. The patients — who lived in the U.S. and Germany — received chemotherapy for six months along with immunotherapy and then continued with immunotherapy alone for another six months. Dr. Sinicrope and others previously studied patients with colon cancer whose cells are unable to repair errors during DNA replication that create a nucleotide mismatch, a condition called dMMR. They noted that these patients' tumors showed a striking increase in inflammatory cells within the tumor, including those that express the target of immune checkpoint inhibitors. This sparked the idea of using immune checkpoint inhibitors to make the immune cells more effective in attacking and killing the cancer cells. Based on the data from this study, Dr. Sinicrope recommends this combination of immunotherapy and chemotherapy treatment to be the new standard treatment for stage 3 deficient mismatch repair colon cancer. The research team plans to approach the National Comprehensive Cancer Network, a nonprofit organization consisting of 33 leading cancer centers, including Mayo Clinic, with this recommendation. The study included patients with Lynch syndrome, the most common form of hereditary colon cancer, as these patients can have tumors that show deficient mismatch repair (dMMR). 'We're changing the paradigm in colon cancer treatment. By using immunotherapy at earlier stages of disease, we are achieving meaningful benefits for our patients,' says Dr. Sinicrope.
Mid East Info
13-05-2025
- Mid East Info
Mayo Clinic researchers identify proteins linked to immunotherapy resistance in metastatic colorectal cancer
Dubai, United Arab Emirates; May, 2025 — A discovery by Mayo Clinic researchers may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer. In findings published in Clinical Cancer Research, the team identified specific proteins — fibronectin and smooth muscle actin — within colorectal cancer tissues that are associated with resistance to immunotherapy treatment. Immunotherapy is a major advance in treating cancer, but many patients, including those with metastatic colorectal cancer, do not respond to it. Until now, researchers have not known why. 'We need predictive biomarkers to guide the selection of immunotherapy for patients,' says medical oncologist and gastroenterologist Frank Sinicrope, M.D. , the senior author of the study. 'Identifying those who may have resistance to treatment can be useful because then we can spare them from receiving treatment that may not be beneficial and could produce significant toxicities.' The research team used digital spatial profiling, an advanced technology that simultaneously analyzes the expression of multiple proteins and where they are located within tissues. This approach allowed researchers to zoom in to get a bird's eye view of a tumor that includes proteins both within and surrounding the tumor cells and how they interact. Dr. Sinicrope compares the spatial tools to an aerial view of a neighborhood where one can see relationships between driveways, houses, yards and neighboring structures. Similarly, this detailed view provides physicians and researchers with critical information about the proteins in and around a patient's cancer, potentially informing the best treatment for the patient. 'We wanted to learn more about the patients who did not respond to immunotherapy. We investigated the leading edge of the tumor where cancer cells are invading and where the immune system is attempting to fight the cancer,' says Dr. Sinicrope. 'It's like a battle going on here and we're getting a snapshot into who is in attendance.' The researchers focused on 10 regions at the invasive margin of a tumor. They applied digital spatial profiling to investigate 71 distinct proteins in both the tumor's epithelial compartment and the surrounding stromal compartment. Fibronectin and smooth muscle actin are two extracellular matrix proteins that were found in the epithelial region of the tumor and were associated with resistance to immunotherapy and shorter time before disease progression. Upon further analysis, the researchers observed that cancer-associated fibroblasts were producing these proteins. The evidence, they say, suggests that these proteins can contribute to suppression of the anti-tumor immune response. The discovery offers a step toward more personalized and effective colorectal cancer treatments.
Mid East Info
10-12-2024
- Mid East Info
Hamdan Bin Rashid Al Maktoum Foundation Participates in the Annual Meeting of the European Talent Support Network (ETSN) in Ljubljana
Hamdan Bin Rashid Al Maktoum Center for Giftedness and Innovation, part of Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences, participated in the Annual Meeting of the European Talent Support Network (ETSN) in Ljubljana, Slovenia, from December 5 to 7, 2024. The gathering brought together 25 talent centers from around the world, providing a pivotal platform to exchange expertise, share achievements, and foster international cooperation in nurturing talent. The event featured panel discussions, presentations on key initiatives, and cultural activities designed to promote knowledge sharing and collaboration. Countries represented included Slovenia, Hungary, the Czech Republic, Croatia, Austria, Lithuania, Greece, Switzerland, Belgium, the Netherlands, Germany, Italy, Spain, Denmark, Ireland, Peru, Turkey, India, and the UAE. Dr. Mariam Al Ghawi, Director of Hamdan Bin Rashid Al Maktoum Center for Talent and Innovation, emphasized the significance of the center's participation, stating: 'Engaging in the ETSN annual meeting underscores our commitment to developing innovative educational strategies that empower gifted individuals. Such global platforms are invaluable for exchanging ideas, sharing best practices, and exploring new ways to foster excellence and innovation in talent development. At the core of our mission is the empowerment of gifted individuals through equitable and inclusive educational solutions that help them realize their full potential.' Dr. Al Ghawi further highlighted the strategic importance of global collaboration: 'Being part of this prestigious international network enhances our ability to integrate global best practices into our programs, reinforcing our capacity to support gifted individuals sustainably. Strengthening these partnerships enables us to achieve excellence in talent development and aligns with our vision of building a brighter future for gifted generations.' At the meeting, Hamdan Bin Rashid Al Maktoum Center presented an in-depth overview of its initiatives, emphasizing the early identification of talent, skill enhancement, and a focus on equity and innovation in education. The center's initiatives received widespread recognition, opening doors for further international partnerships and collaborations. This participation reflects the center's enduring commitment to establishing itself as a global leader in talent development. By fostering sustainable and innovative educational solutions, the center is paving the way for excellence in gifted education and preparing the next generation to address the challenges of the future.
